Objectives: Surfactant protein D (SP-D) is a member of the collectin family of proteins, which are involved in host defense mechanisms in the lung. In the present study, we found that SP-D is produced in the human prostate where it may play a role in innate immunity.

Methods And Results: Using reverse-transcriptase PCR and Western blot analysis, we demonstrate that SP-D mRNA and protein are present in human prostate tissue. In situ hybridization and immunohistochemistry revealed that SP-D mRNA and protein are localized in epithelial cells of prostate glands. Prostate glands that are surrounded by inflammatory cells produce increased amounts of SP-D protein. We also show that SP-D inhibits the infection of LNCaP and P69SV40T prostate epithelial cells by Chlamydia trachomatis in an in vitro infection assay. Furthermore, using truncated human SP-D mutants, we demonstrate that SP-D binds to Chlamydia trachomatis via its carboxy-terminal lectin domains.

Conclusions: Our in vitro studies suggest that SP-D protects the prostate from infection by pathogens. SP-D protein levels are increased at sites of inflammation in the prostate, suggesting SP-D may also contribute more generally to inflammatory regulation in the prostate.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20292DOI Listing

Publication Analysis

Top Keywords

human prostate
12
sp-d
11
prostate
9
surfactant protein
8
protein sp-d
8
demonstrate sp-d
8
sp-d mrna
8
mrna protein
8
epithelial cells
8
prostate glands
8

Similar Publications

Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.

View Article and Find Full Text PDF

A cross-tissue transcriptome-wide association study identifies new susceptibility genes for benign prostatic hyperplasia.

Sci Rep

January 2025

Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, People's Republic of China.

Benign prostatic hyperplasia (BPH) is a prevalent urinary system disorder. Despite evidence of a significant genetic component from previous studies, the specific pathogenic genes and biological mechanisms are still largely unknown. The study utilized the FinnGen R10 dataset, encompassing 177,901 individuals (36,601 cases and 141,300 controls), and the GTEx v8 EQTLs files to conduct single-tissue and cross-tissue transcriptome-wide association studies (TWAS).

View Article and Find Full Text PDF

We intended to investigate the potential of several transitional zone (TZ) volume-related variables for the detection of clinically significant prostate cancer (csPCa) among lesions scored as Prostate Imaging Reporting and Data System (PI-RADS) category 3. Between September 2018 and August 2023, patients who underwent mpMRI examination and scored as PI-RADS 3 were queried from our institution. The diagnostic performances of prostate-specific antigen density (PSAD), TZ-adjusted PSAD (TZPSAD), and TZ-ratio (TZ volume/whole gland prostate volume) were analyzed.

View Article and Find Full Text PDF

High-intensity focused ultrasound ablation to increase tumor-specific lymphocytes in prostate cancer.

Transl Oncol

January 2025

Department of Urology, Cedars Sinai Medical Center, 8635 W. Third St, 1070, Los Angeles, CA 90048, United States. Electronic address:

Treatment options for localized prostate cancer have been expanded by FDA-approval of High-Intensity Focused Ultrasound (HIFU). Prostate cancer typically has few tumor-infiltrating lymphocytes, which are crucial for antitumor immunity. This study investigated the use of HIFU to increase lymphocyte infiltration into the tumor and enhance antitumor immunity.

View Article and Find Full Text PDF

Purpose: This study aimed to identify if a subset of men can safely avoid or delay prostate biopsy based on negative results of prostate-specific membrane antigen positron emission tomography (PSMA-PET).

Materials And Methods: Among 341 consecutive cases in a prospective biopsy cohort (NCT05073653), 111 treatment-naïve men with negative PSMA-PET (PRIMARY-score 1/2) were included. All participants underwent PSMA-PET and histopathological examinations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!